Your browser doesn't support javascript.
loading
Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies.
Gao, Xiang; Fujii, Toshimitsu; Ye, Byong Duk; Chou, Jen-Wei; Sugimoto, Ken; Cao, Qian; Kligys, Kristina; Murakoshi, Kaoru; Teng, Dennis; Zhang, Yafei; Nakase, Hiroshi.
  • Gao X; Department of Gastroenterology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Fujii T; Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Ye BD; Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Chou JW; Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
  • Sugimoto K; First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Cao Q; Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Kligys K; AbbVie Inc., North Chicago, Illinois, USA.
  • Murakoshi K; AbbVie GK, Tokyo, Japan.
  • Teng D; AbbVie Pte. Ltd., Singapore, Singapore.
  • Zhang Y; AbbVie Inc., North Chicago, Illinois, USA.
  • Nakase H; Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
J Gastroenterol Hepatol ; 39(1): 55-65, 2024 Jan.
Article en En | MEDLINE | ID: mdl-37788676

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Crohn Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Crohn Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article